Multivariable analysis of factors associated with nonadherence to primary prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia (PCP) – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

*<p>In addition to adjusting for variables included in this table, we controlled for region of residence in the U.S. and year of SHAS interview.</p>†<p>P-value<0.05.</p

Demographic characteristics, behavioral risk factors, HIV testing history, and use of prevention services among 780 men who have sex with men who attended Gay Pride and Minority Gay Pride events in 7 U.S. cities by circumcision status – 2006.

*<p>Respondents could select more than one race.</p>†<p>Other race includes American Indians/Alaskan Native, Asians/Native Hawaiians/Pacific Islanders, and people reporting “other” race.</p>‡<p>Two respondents reported >10 male partners.</p>§<p>For this question, n = 777 because 3 respondents answered ‘don't know.’</p

Willingness to be circumcised among 127 uncircumcised men who have sex with men not known to be HIV-infected who attended Gay Pride and Minority Gay Pride events in 7 U.S. cities – 2006.

*<p>Median age of respondents was 33 years.</p

Demographic characteristics, behavioral risk factors, HIV testing history, and use of prevention services and agreement with perceived risks and benefits of circumcision and willingness to be circumcised among 133 uncircumcised men who have sex with men not known to be HIV-infected who attended Gay Pride and Minority Gay Pride events in 7 U.S. cities by willingness to be circumcised as an adult – 2006.

*<p>Respondents could select more than one race.</p>†<p>Other race includes American Indians/Alaskan Native, Asians/Native Hawaiians/Pacific Islanders, and people reporting “other” race.</p>‡<p>Five uncircumcised respondents did not provide data for the perceived risks and benefits statements, therefore N = 127.</p

Primary reason for not taking medications to prevent <i>Pneumocystis jirovecii</i> pneumonia (PCP) listed by 264 persons who were nonadherent with primary PCP prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

<p>Primary reason for not taking medications to prevent <i>Pneumocystis jirovecii</i> pneumonia (PCP) listed by 264 persons who were nonadherent with primary PCP prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.</p

Characteristics of 1,666 persons with HIV infection prescribed primary prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia (PCP), by nonadherence to prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

*<p>Column percentages may not total 100% because of rounding.</p>†<p>P-value <0.05 when comparing persons nonadherent with those adherent to PCP prophylaxis.</p>‡<p>Regions defined by U.S. Census Bureau; for SHAS sites included in this analysis, Northeast comprises NJ, CT, and PA; South comprises GA, MD, FL, SC, DE, and TX; Midwest comprises IL, KS, MI, and MN; and West comprises AZ, CA, CO, NM, and WA.</p>±<p>Other responses included correctional institution, refused to answer, and other responses which did not fit into the listed response categories.</p>§<p>Categories are mutually exclusive.</p>||<p>Defined as answering yes to at least 2 of the CAGE screening questions and reporting alcohol use in the past year.</p

Characteristics of Male and Female Survey Participants Who Were Sexually Active in the 12 Months before an Anonymous Self-administered Survey, Chuuk, Federated States of Micronesia, June 2001.

a<p>For each of the variables representing characteristics of male or female participants, any variation in the denominator is due to missing information (incomplete responses) among the total number (n) of individuals who participated in the survey.</p>b<p>Information available for 86 female and 66 male participants; p<0.01, Wilcoxon rank-sum test.</p>c<p>Information available for 74 female and 59 male participants; p<0.01, Wilcoxon rank-sum test.</p